AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke "ARCADIA"


Phase 3 Results N/A

Summary of Purpose

Objectives - Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy. - Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 17 February 2018.

19 Jan 2018 16 Jun 2017 18 Jan 2022 30 Apr 2022 1 Feb 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

Not available